{
  "meta": {
    "title": "21_Viral_Hepatitis",
    "url": "https://brainandscalpel.vercel.app/21-viral-hepatitis-0996ec9e.html",
    "scrapedAt": "2025-11-30T12:28:30.567Z"
  },
  "questions": [
    {
      "text": "Which among the following hepatitis viruses is a DNA virus?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis A"
        },
        {
          "id": 2,
          "text": "Hepatitis B"
        },
        {
          "id": 3,
          "text": "Hepatitis C"
        },
        {
          "id": 4,
          "text": "Hepatitis D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Hepatitis B</strong>&nbsp;is a <strong>DNA </strong>virus.</p>\n<p>The hepatotropic viruses include:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Hepatitis virus&nbsp;</strong></td>\n<td><strong>Family</strong></td>\n<td><strong>Genetic material</strong></td>\n</tr>\n<tr>\n<td>A</td>\n<td>Picorna virus</td>\n<td>RNA</td>\n</tr>\n<tr>\n<td>B</td>\n<td>Hepadna virus</td>\n<td>DNA</td>\n</tr>\n<tr>\n<td>C&nbsp;</td>\n<td>Flavivirus</td>\n<td>RNA</td>\n</tr>\n<tr>\n<td>D&nbsp;</td>\n<td>Deltavirus</td>\n<td>RNA</td>\n</tr>\n<tr>\n<td>E</td>\n<td>Hepeviridae&nbsp;</td>\n<td>RNA</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0882",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is the most common route of spread of hepatitis E virus?",
      "choices": [
        {
          "id": 1,
          "text": "Sexual transmission"
        },
        {
          "id": 2,
          "text": "Blood transfusion"
        },
        {
          "id": 3,
          "text": "Feco-oral"
        },
        {
          "id": 4,
          "text": "IV drug use"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most common route of the spread of <strong>hepatitis E</strong> is&nbsp;<strong>feco-oral</strong>.&nbsp;</p>\n<p>Hepatitis E virus is the <strong>most common </strong>cause of <strong>acute</strong> hepatitis in <strong>adults</strong>, especially in endemic countries like India. The most common cause of acute hepatitis in <strong>children</strong>&nbsp;is the&nbsp;<strong>hepatitis A</strong> virus.&nbsp;</p>\n<p><span>Routes of transmission of hepatitis viruses:</span></p>\n<table>\n<tbody>\n<tr>\n<td><span><strong>Hepatitis</strong></span></td>\n<td><span><strong>Vertical route</strong></span></td>\n<td><span><strong>Needle</strong></span></td>\n<td><span><strong>Blood transfusion</strong></span></td>\n<td><span><strong>Sexual</strong></span></td>\n<td><span><strong>Feco-oral</strong></span></td>\n</tr>\n<tr>\n<td><span>Hep B</span></td>\n<td>\n<p><span>HBeAg positive mother &gt;90%</span></p>\n<p><span>HBsAg with Anti-HBe mother 10-15%</span></p>\n</td>\n<td><span>6-30%</span></td>\n<td>\n<p><span>1 in 2 lakh</span></p>\n<p><span>(Most common blood transfusion-related virus).</span></p>\n</td>\n<td><span>Variable</span></td>\n<td><span>&nbsp;-</span></td>\n</tr>\n<tr>\n<td><span>Hep C</span></td>\n<td><span>5%</span></td>\n<td><span>1.8-6%</span></td>\n<td><span>1 in 18 lakh</span></td>\n<td><span>5%</span></td>\n<td><span>&nbsp;-</span></td>\n</tr>\n<tr>\n<td><span>Hep A</span></td>\n<td><span>Nil</span></td>\n<td><span>Nil</span></td>\n<td><span>Rare&nbsp;</span></td>\n<td><span>Rare</span></td>\n<td><strong><span>Most common</span></strong></td>\n</tr>\n<tr>\n<td><span>Hep E</span></td>\n<td><span>Rare&nbsp;</span></td>\n<td><span>Nil&nbsp;</span></td>\n<td><span>Nil</span></td>\n<td><span>Nil</span></td>\n<td><strong><span>Most common</span></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6884",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true regarding hepatitis E?",
      "choices": [
        {
          "id": 1,
          "text": "Can be fatal in pregnant women"
        },
        {
          "id": 2,
          "text": "Can cause chronic hepatitis in immunocompetent"
        },
        {
          "id": 3,
          "text": "Most common route of spread is vertical transmission"
        },
        {
          "id": 4,
          "text": "Has a carrier state"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Fatality </strong>due to<strong> Hepatitis E</strong>&nbsp;is&nbsp;highest&nbsp;in&nbsp;<strong>pregnant </strong>women. In the general population, hepatitis E can lead to fatal fulminant hepatitis in only 1&ndash;2% of cases. However, in pregnant women, this is raised to <strong>20%&nbsp;</strong>of cases.&nbsp;</p>\n<p>HEV does not have a carrier state and can cause chronic hepatitis only in immunocompromised individuals. Its most common route of spread is feco-oral.</p>\n<p>Note - <strong>HEV</strong> is also known as <strong>E-NANB</strong>, i.e., <strong>E</strong>nterically transmitted <strong>N</strong>on-<strong>A</strong> <strong>N</strong>on-<strong>B</strong>&nbsp;hepatitis virus.It often appears in epidemics; hence, it is also called epidemic NANB.</p><hr><h3>Related Pearl: The most commons in hepatitis</h3><table>\n<tbody>\n<tr>\n<td><strong>CAUSE</strong></td>\n<td><strong>ETIOLOGICAL AGENT</strong></td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatitis</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis in children</td>\n<td>HepA</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis in adults</td>\n<td>HepE</td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatitis in pregnancy</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis related mortality in pregnancy</td>\n<td>HepE</td>\n</tr>\n<tr>\n<td>Most common cause of acute liver failure (Western countries)</td>\n<td>Paracetamol poisoning</td>\n</tr>\n<tr>\n<td>Most common cause of acute liver failure in India</td>\n<td> Viral hepatitis (B and E)</td>\n</tr>\n<tr>\n<td>Most common cause of viral fulminant hepatitis</td>\n<td> HepE</td>\n</tr>\n<tr>\n<td>Highest risk of progresion from acute viral hepatitis to fulminant hepatitis</td>\n<td>HepD </td>\n</tr>\n<tr>\n<td>Most common cause of chronic hepatitis (prevalence)</td>\n<td>HepB (450 million)</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis, leading to chronic<br />hepatitis (prevalence)</td>\n<td> HepC (150 million)</td>\n</tr>\n<tr>\n<td>Maximum risk and max potential of chronicity</td>\n<td>HepC</td>\n</tr>\n<tr>\n<td>Most common cause of carrier State</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of cirrhosis</td>\n<td>Alcohol</td>\n</tr>\n<tr>\n<td>Most common viral cause of cirrhosis</td>\n<td>HepC</td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatocellular carcinoma</td>\n<td>HepB</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0980",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is associated with the highest risk of developing fulminant hepatitis?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis A"
        },
        {
          "id": 2,
          "text": "Hepatitis B"
        },
        {
          "id": 3,
          "text": "Hepatitis E"
        },
        {
          "id": 4,
          "text": "Hepatitis D"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Acute viral hepatitis caused by<strong>&nbsp;</strong>the <strong>h</strong><strong>epatitis D </strong>virus is associated with the&nbsp;<strong>highest risk</strong> of developing <strong>fulminant</strong> <strong>hepatitis</strong>.</p>\n<p>However, <strong>fulminant hepatitis</strong> is <strong>most commonly</strong> caused by&nbsp;<strong>h</strong><strong>epatitis E</strong>,&nbsp;especially in endemic countries such as India. This is due to the greater prevalence of hepatitis E infections compared to hepatitis D.</p><hr><h3>Related Pearl: The most commons in hepatitis</h3><table>\n<tbody>\n<tr>\n<td><strong>CAUSE</strong></td>\n<td><strong>ETIOLOGICAL AGENT</strong></td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatitis</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis in children</td>\n<td>HepA</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis in adults</td>\n<td>HepE</td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatitis in pregnancy</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis related mortality in pregnancy</td>\n<td>HepE</td>\n</tr>\n<tr>\n<td>Most common cause of acute liver failure (Western countries)</td>\n<td>Paracetamol poisoning</td>\n</tr>\n<tr>\n<td>Most common cause of acute liver failure in India</td>\n<td> Viral hepatitis (B and E)</td>\n</tr>\n<tr>\n<td>Most common cause of viral fulminant hepatitis</td>\n<td> HepE</td>\n</tr>\n<tr>\n<td>Highest risk of progresion from acute viral hepatitis to fulminant hepatitis</td>\n<td>HepD </td>\n</tr>\n<tr>\n<td>Most common cause of chronic hepatitis (prevalence)</td>\n<td>HepB (450 million)</td>\n</tr>\n<tr>\n<td>Most common cause of acute viral hepatitis, leading to chronic<br />hepatitis (prevalence)</td>\n<td> HepC (150 million)</td>\n</tr>\n<tr>\n<td>Maximum risk and max potential of chronicity</td>\n<td>HepC</td>\n</tr>\n<tr>\n<td>Most common cause of carrier State</td>\n<td>HepB</td>\n</tr>\n<tr>\n<td>Most common cause of cirrhosis</td>\n<td>Alcohol</td>\n</tr>\n<tr>\n<td>Most common viral cause of cirrhosis</td>\n<td>HepC</td>\n</tr>\n<tr>\n<td>Most common cause of viral hepatocellular carcinoma</td>\n<td>HepB</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0904",
      "difficulty": "medium"
    },
    {
      "text": "A pregnant woman comes to your clinic for her first antenatal checkup in her 3rd trimester. Laboratory workup reveals that she is HBsAg positive and HBeAg positive. What is the chance of vertical transmission of hepatitis B to the child?",
      "choices": [
        {
          "id": 1,
          "text": "25-30%"
        },
        {
          "id": 2,
          "text": "50%"
        },
        {
          "id": 3,
          "text": "10-15%"
        },
        {
          "id": 4,
          "text": ">90 %"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The chance of <strong>vertical transmission</strong> of hepatitis B from a mother who is <strong>HBsAg positive </strong>and <strong>HBeAg positive </strong>is <strong>&gt;90%</strong>.&nbsp;In contrast, when the mother is HBsAg positive but HBeAg negative or HBsAg positive with Anti Hbe, the risk of vertical transmission is low.</p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;WHO recommends that pregnant women testing positive for HBV infection (HBsAg positive) with HBV DNA &ge; 200,000 IU/mL should receive Tenofovir prophylaxis from the 28th week of pregnancy until birth, to prevent mother-to-child transmission of HBV. This is in addition to three-dose hepatitis B vaccination in all infants.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">To prevent vertical transmission of HBV, HBsAg positive pregnant women with high HBV DNA titres s</span><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;WHO recommends that pregnant women testing positive for HBV infection (HBsAg positive) with HBV DNA &ge; 200,000 IU/mL should receive Tenofovir prophylaxis from the 28th week of pregnancy until birth, to prevent mother-to-child transmission of HBV. This is in addition to three-dose hepatitis B vaccination in all infants.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">hould receive <strong>tenofovir prophylaxis</strong> from the <strong>28th week </strong>of pregnancy<strong> until birth. I</strong></span><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;WHO recommends that pregnant women testing positive for HBV infection (HBsAg positive) with HBV DNA &ge; 200,000 IU/mL should receive Tenofovir prophylaxis from the 28th week of pregnancy until birth, to prevent mother-to-child transmission of HBV. This is in addition to three-dose hepatitis B vaccination in all infants.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\"><strong>nfants</strong> born to these women are given <strong>hepatitis B immunoglobulin</strong>&nbsp;along with the first dose of the&nbsp;<strong>hepatitis B vaccine.&nbsp;</strong></span></p>\n<p>The presence of <strong>HBeAg</strong> indicates active replication of HBV. Therefore, HBeAg is the <strong>qualitative</strong> marker of <strong>infectivity</strong>. <strong>HBV DNA</strong> titre is the <strong>quantitative</strong> marker of infectivity.&nbsp;</p>\n<p>Routes of transmission of hepatitis viruses:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Hepatitis</strong></td>\n<td><strong>Hep B</strong></td>\n<td><strong>Hep C</strong></td>\n<td><strong>Hep A</strong></td>\n<td><strong>Hep E</strong></td>\n</tr>\n<tr>\n<td><strong>Vertical route</strong></td>\n<td>\n<p><span>HBsAg and HBeAg positive mother &gt;90%</span></p>\n<p><span>HBsAg positive with Anti HBe mother- 10-15%</span></p>\n</td>\n<td>5%</td>\n<td><span>Nil</span></td>\n<td><span>Rare</span></td>\n</tr>\n<tr>\n<td><strong>Needle</strong></td>\n<td>6-30%</td>\n<td>1.8-6 %&nbsp;</td>\n<td><span>Nil</span></td>\n<td><span>Nil&nbsp;</span></td>\n</tr>\n<tr>\n<td><strong>Blood transfusion</strong></td>\n<td><span>1 in 2 lakh<br /></span><span>(Most common blood transfusion-related virus)</span></td>\n<td><span>1 in 18 lakh</span></td>\n<td><span>Rare</span></td>\n<td><span>Nil</span></td>\n</tr>\n<tr>\n<td><strong>Sexual</strong></td>\n<td><span>Variable</span></td>\n<td><span>Yes</span></td>\n<td><span>Rare</span></td>\n<td><span>Nil</span></td>\n</tr>\n<tr>\n<td><strong>Feco-oral</strong></td>\n<td>-</td>\n<td>-</td>\n<td><span>Most common</span>&nbsp;</td>\n<td>&nbsp;<span>Most common</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0967",
      "difficulty": "medium"
    },
    {
      "text": "What is the first marker to rise in a patient with acute hepatitis B?",
      "choices": [
        {
          "id": 1,
          "text": "Anti-HBs"
        },
        {
          "id": 2,
          "text": "HBsAg"
        },
        {
          "id": 3,
          "text": "HBeAg"
        },
        {
          "id": 4,
          "text": "Anti-HBc"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>first</strong> virologic marker to rise in acute hepatitis B is<strong> HBsAg</strong> i.e., Hepatitis B surface antigen.&nbsp;It is detectable in serum <strong>within 1&ndash;12 weeks </strong>of infection.&nbsp;Usually, HBsAg becomes undetectable 1&ndash;2 months after the onset of jaundice. If it persists <strong>beyond 6 months</strong>, it indicates <strong>chronic hepatitis B</strong>.</p>\n<p>However, very rarely, patients may have an <strong>HBsAg</strong> <strong>negative</strong> status even during <strong>active infection</strong> due to infection with <strong>escape mutant </strong>HBV. These escape mutants have mutations within the S gene and they&nbsp;are known to be responsible for occult hepatitis B infections.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/51c2de547f714f7ab327d295ec860e0fx1279x1466.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6902",
      "difficulty": "easy"
    },
    {
      "text": "Which serological marker can be used to diagnose acute hepatitis B in the window period?",
      "choices": [
        {
          "id": 1,
          "text": "Anti HBs"
        },
        {
          "id": 2,
          "text": "HBsAg"
        },
        {
          "id": 3,
          "text": "HBeAg"
        },
        {
          "id": 4,
          "text": "Anti HBc"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The diagnosis of acute hepatitis B in the <strong>window period </strong>or<strong> serological gap&nbsp;</strong>can be made by the detection of the <strong>a</strong><strong>nti-HBc antibody.</strong></p>\n<p class=\"p1\">The window period is the&nbsp;period between the <strong>disappearance of HBsAg</strong> to <strong>anti-HBs seroconversion</strong>.&nbsp;During this window period,&nbsp;anti-HBc is the only detectable antibody.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p> </p>\n<table>\n<tbody>\n<tr>\n<td> <strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6903",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old male patient presented with right upper quadrant abdominal pain and jaundice. His lab reports are given below. What is the likely causative organism for his condition?<div class='question-desc-html'><p>Total bilirubin - 20 mg/dL</p>\n<p>AST - 450 IU/L</p>\n<p>ALT - 400 IU/L</p>\n<p>HBsAg +ve</p>\n<p>HBeAg -ve</p>\n<p>HBV DNA - 50000 IU/mL</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "HBV surface mutant"
        },
        {
          "id": 2,
          "text": "HBV precore mutant"
        },
        {
          "id": 3,
          "text": "HBV escape mutatnt"
        },
        {
          "id": 4,
          "text": "Vaccine-derived HBV"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span><strong>Increased viral load</strong> and <strong>negative HBeAg</strong> suggest a <strong>pre-core mutant</strong> variety of hepatitis B virus.</span><span>&nbsp;</span><span>These strains have mutations in the <strong>pre-core region</strong> of the <strong>C gene</strong>, leading to a stop codon that prevents HBeAg synthesis. These strains can be detected in the serum by <strong>HBV DNA analysis</strong>.&nbsp;</span></p>\n<p><span>Infection with hepatitis B mutants is d</span><span>ifficult to treat and causes</span><span>&nbsp;infections of prolonged duration. They have a</span><span>&nbsp;higher risk of progressing to liver cirrhosis.&nbsp;<sup id=\"cite_ref-pmid15280461_4-0\" class=\"reference\"></sup></span></p>\n<p><span>Types of hepatitis B mutants are:</span></p>\n<table>\n<tbody>\n<tr>\n<td><span><strong>Type&nbsp;</strong></span></td>\n<td><span><strong>Feature</strong></span></td>\n</tr>\n<tr>\n<td><span>Pre-core mutants</span></td>\n<td>\n<p><span>Defect in pre-core region C</span></p>\n<p><span>No HBeAg</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Escape mutants</span></td>\n<td>\n<p><span>Mutation in S region</span></p>\n<p><span>HBsAg resists neutralisation by anti-HBs</span></p>\n<p><span>Seen in</span></p>\n<ul>\n<li><span>Infants born to HBeAg positive mothers</span></li>\n<li><span>Liver transplant recipient</span></li>\n<li><span>Associated with passive and active immunization</span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><span>YMDD mutation</span></td>\n<td>\n<p><span>Mutation in P region i.e. YMDD locus which codes for</span><span>&nbsp;reverse transcriptase</span></p>\n<p><span>Seen in patients on lamivudine therapy</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6907",
      "difficulty": "medium"
    },
    {
      "text": "The lab report of a 40-year-old man is shown below. What is the most likely cause for this serological picture?<div class='question-desc-html'><p>HBsAg -ve</p>\n<p>Anti-HBs -ve</p>\n<p>IgG anti-HBc +ve</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Recovering from hepatitis B"
        },
        {
          "id": 2,
          "text": "Hepatitis B in the remote past"
        },
        {
          "id": 3,
          "text": "Immunization with hepatitis B vaccine"
        },
        {
          "id": 4,
          "text": "Window period of HBV infection"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given lab findings are most likely to be in patients who had&nbsp;<strong>hepatitis B </strong>in the<strong> remote past </strong>i.e., patients in&nbsp;<strong>late convalescence&nbsp;</strong>period.<strong>&nbsp;</strong>In such conditions, the patient will have <strong>positive IgG anti-HBc</strong> and <strong>negative HBsAg</strong>.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p> </p>\n<table>\n<tbody>\n<tr>\n<td> <strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6906",
      "difficulty": "medium"
    },
    {
      "text": "A patient with acute hepatitis B has recovered from the infection. Identify the serological marker marked in the image:",
      "choices": [
        {
          "id": 1,
          "text": "Anti-HBc Ab"
        },
        {
          "id": 2,
          "text": "Anti-HBs Ab"
        },
        {
          "id": 3,
          "text": "Anti-HBe Ab"
        },
        {
          "id": 4,
          "text": "HBsAg"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>serological marker</strong> marked in the image which becomes <strong>detectable early</strong> in the infection and <strong>remains elevated </strong>for a<strong> long period</strong> <strong>after recovery</strong> from the infection is an <strong>anti-HBc </strong>antibody.</p>\n<p>Anti-HBc is demonstrable in serum within the first <strong>1&ndash;2 weeks</strong> <strong>after</strong> the appearance of <strong>HBsAg</strong>. It precedes detectable levels of anti-HBs by weeks to months.</p>\n<p><strong>IgM anti-HBcAg</strong> <strong>antibody</strong> is seen <strong>early</strong> in the infection for about <strong>6 months</strong> and indicates a <strong>recent infection</strong>. <strong>IgG anti-HBcAg antibody</strong> is seen later, <strong>after 6 months</strong>, and indicates <strong>remote infection</strong>.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p> </p>\n<table>\n<tbody>\n<tr>\n<td> <strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f38348cf349a4c52b765156a02f3225e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0227",
      "difficulty": "medium"
    },
    {
      "text": "An intern sustained a needle-prick injury while establishing an IV line on a patient in the casualty. The patient was subsequently found to be HBsAg positive. The presence of which of the following markers in the intern would reliably indicate an early infection?",
      "choices": [
        {
          "id": 1,
          "text": "IgM anti HBsAg"
        },
        {
          "id": 2,
          "text": "IgM anti HBc"
        },
        {
          "id": 3,
          "text": "HBsAg"
        },
        {
          "id": 4,
          "text": "HBeAg"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>most reliable </strong>indicator of recent HBV infection is<strong> IgM anti-HBc</strong> in serum. However, the <strong>first</strong> virologic marker to rise in acute hepatitis B is<strong> HBsAg</strong> i.e. surface antigen.</p>\n<p><strong>HBsAg</strong> is detectable in serum <strong>within 1–12 weeks </strong>of infection. <strong>Anti-HBc</strong> is demonstrable in the serum about <strong>1-2 weeks after</strong> this, and may sometimes persist in the serum even longer than an anti-HBs antibody. <strong>IgM</strong> anti-HBcAg is seen early in the infection and persists for about 6 months. It indicates a <strong>recent infection</strong>. <strong>IgG</strong> anti-HBcAg antibody is seen later i.e. after 6 months and indicates <strong>remote infection</strong>.</p>\n<p>HBcAg is not detectable in the serum of patients with HBV infection as it is present intracellularly. </p>\n<p>Note: The risk of transmission of HBV from percutaneous routes (eg., needle prick) is about 6-30% and it is about 100 times more infectious than HIV. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0919",
      "difficulty": "medium"
    },
    {
      "text": "During your casualty rotation, you accidentally injure yourself while suturing a patient. You had taken the full schedule of hepatitis B vaccination during your first year of medical school. Which of the following markers will you get measured to determine the need for HBIG administration?",
      "choices": [
        {
          "id": 1,
          "text": "Anti HBeAg"
        },
        {
          "id": 2,
          "text": "IgM Anti HBc"
        },
        {
          "id": 3,
          "text": "IgG Anti HBc"
        },
        {
          "id": 4,
          "text": "Anti HBsAg"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The need for administration of hepatitis B hyperimmune globulin (<strong>HBIG</strong>) in a <strong>previously vaccinated</strong> individual can be determined based on <strong>anti-HBsAg levels</strong>. It is the marker for determining the efficacy of hepatitis B vaccination.</p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>The complete <strong>hepatitis B vaccine</strong> schedule consists of three<strong>&nbsp;intramuscular doses</strong>&nbsp;at <strong>0, 1, and 6 months</strong>.</p>\n</div>\n</div>\n<p><strong>Post Exposure Prophylaxis:</strong></p>\n<p>The prophylaxis can be done using the hepatitis B vaccine or hepatitis B immunoglobulin (HBIG).</p>\n<table>\n<tbody>\n<tr>\n<td>Vaccination status of the exposed person</td>\n<td>Recommended prophylaxis</td>\n</tr>\n<tr>\n<td>Unvaccinated</td>\n<td>HBIG (0.06 mL/kg) and initiate hepatitis B vaccine series</td>\n</tr>\n<tr>\n<td>Known responder to previous vaccination (<strong>anti-HBs titer&gt;10 mIU/ml</strong>)</td>\n<td>No action required</td>\n</tr>\n<tr>\n<td>Non-responder to previous vaccination (<strong>anti-HBs titre &lt;10 mIU/ml</strong>)</td>\n<td>HBIG: 2 doses (1 month apart)&nbsp;OR&nbsp;HBIG: 1 dose + initiate hepatitis B revaccination.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p> </p>\n<table>\n<tbody>\n<tr>\n<td> <strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0968",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following markers can be used to differentiate between hepatitis D superinfection and coinfection?",
      "choices": [
        {
          "id": 1,
          "text": "IgM anti-HDV"
        },
        {
          "id": 2,
          "text": "IgM anti-HBc"
        },
        {
          "id": 3,
          "text": "HBV DNA"
        },
        {
          "id": 4,
          "text": "HBsAg"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>IgM anti-HBc</strong>&nbsp;can be used to <strong>differentiate</strong> between&nbsp;hepatitis D<strong> coinfection </strong>and<strong> superinfection </strong>in patients with HBV infection.&nbsp;</p>\n<p><strong>Co-infection:</strong></p>\n<ul>\n<li>Simultaneous infection with both HBV and HDV</li>\n<li>IgM anti-HBc&nbsp;<strong>detectable</strong>&nbsp;in co-infection as its presence indicates recent infection</li>\n</ul>\n<p><strong>Superinfection</strong>:</p>\n<ul>\n<li>HDV infection of an individual chronically infected with HBV</li>\n<li>IgM anti-HBc will <strong>not be detectable</strong></li>\n<li><strong>IgG anti-HBc</strong> will be present</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1003",
      "difficulty": "medium"
    },
    {
      "text": "A male patient presents with complaints of jaundice, loss of appetite, and weight loss for the past several months. After a full laboratory workup, a liver biopsy was performed which appeared as shown in the given image. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Acute hepatitis A"
        },
        {
          "id": 2,
          "text": "Chronic hepatitis B"
        },
        {
          "id": 3,
          "text": "Chronic hepatitis C"
        },
        {
          "id": 4,
          "text": "Chronic hepatitis A"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given histopathological image shows&nbsp;<strong>ground-glass hepatocytes </strong>which are a hallmark of<strong> chronic hepatitis B</strong><strong>&nbsp;</strong>infection.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fdb81691f8794ee6b43612d6a6db1725x1280x1157.JPEG\" alt=\"Explanation Image\"><p>These ground-glass hepatocytes are liver parenchymal cells that have an eosinophilic, granular, and glassy appearance on light microscopy. This appearance is due to the <strong>accumulation of</strong> <strong>HBsAg</strong>&nbsp;(hepatitis B surface antigen)<strong>&nbsp;</strong>in the<strong>&nbsp;smooth endoplasmic reticulum.</strong></p>\n<p><strong>Liver biopsy findings in viral hepatitis</strong>:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Virus</strong></td>\n<td><strong>Liver Biopsy Findings</strong></td>\n</tr>\n<tr>\n<td>Hepatitis A</td>\n<td>Hepatocyte swelling, monocyte infiltration, Councilman bodies</td>\n</tr>\n<tr>\n<td><strong>Hepatitis B&nbsp;</strong></td>\n<td><strong>Ground glass appearance&nbsp;</strong></td>\n</tr>\n<tr>\n<td>Hepatitis C&nbsp;</td>\n<td>Lymphoid aggregates with a focal area of macrovesicular steatosis&nbsp;</td>\n</tr>\n<tr>\n<td>Hepatitis D</td>\n<td>Similar to HBV&nbsp;</td>\n</tr>\n<tr>\n<td>Hepatitis E</td>\n<td>Patchy necrosis</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/7a1becbf69474b7f819e616c722e43f4.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0899",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following pairs of viral hepatitis and its management is incorrectly matched?",
      "choices": [
        {
          "id": 1,
          "text": "Acute viral hepatitis E - Supportive care"
        },
        {
          "id": 2,
          "text": "Acute viral hepatitis B - Antiviral therapy"
        },
        {
          "id": 3,
          "text": "Acute viral hepatitis A - Supportive care"
        },
        {
          "id": 4,
          "text": "Acute  viral hepatitis C - Antiviral therapy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Antiviral</strong> <strong>therapy</strong> is not indicated in acute hepatitis B infection. It is only indicated in <strong>chronic hepatitis B.</strong></p>\n<p>The majority of <strong>acute hepatitis</strong> (<strong>A</strong>, <strong>B</strong>, and<strong> E</strong>) infections are <strong>self-limiting</strong>, resulting in viral elimination and complete healing within 6 months. Hence, they need only <strong>supportive management</strong>. Only 5% of acute hepatitis infections become chronic.&nbsp;</p>\n<p>In acute hepatitis C infection, recovery is rare, and the risk of progression to chronic hepatitis is high(&sim;85%). Thus antiviral therapy is started irrespective of the disease stage.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0998",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an indication for antiviral therapy in chronic hepatitis B infection?",
      "choices": [
        {
          "id": 1,
          "text": "IgG anti-HBc positive"
        },
        {
          "id": 2,
          "text": "HbeAg negative with HBV DNA <2000 IU/L"
        },
        {
          "id": 3,
          "text": "ALT > 2 times upper limit of normal"
        },
        {
          "id": 4,
          "text": "Normal Fibroscan report with ALT < 2 ULN"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>ALT &gt; 2 times</strong> upper limit of normal is an <strong>indication</strong> for <strong>antiviral</strong> therapy in <strong>chronic hepatitis B</strong> infection.</p>\n<p>The decision to initiate antiviral therapy is primarily based on the presence or absence of&nbsp;<strong>cirrhosis</strong>, and&nbsp;parameters such as&nbsp;<strong>HBeAg</strong>,&nbsp;alanine aminotransferase (<strong>ALT</strong>) level, and&nbsp;<strong>HBV DNA</strong> level.</p>\n<p>The following are the indications for starting antivirals in chronic hepatitis B:&nbsp;</p>\n<ul>\n<li aria-level=\"1\">Patients without cirrhosis</li>\n<ul>\n<li aria-level=\"2\">HBeAg + with HBV DNA &gt;20,000 IU/mL and ALT level &gt;2 times the upper limit of normal</li>\n<li aria-level=\"2\">HBeAg -ve with HBV DNA &gt;2000 IU/mL and ALT level &gt;2 times the upper limit of normal</li>\n</ul>\n<li aria-level=\"1\">Patients with compensated cirrhosis and an HBV DNA &gt;2000 IU/mL</li>\n<li>Patients developing acute liver failure or decompensated cirrhosis</li>\n</ul>\n<p>Recommended&nbsp;<strong>first-line antiviral</strong> drugs:</p>\n<ul>\n<li>Entecavir</li>\n<li>Tenofovir alafenamide</li>\n<li>Tenofovir disoproxil fumarate&nbsp;</li>\n</ul>\n<p>Pegylated interferon alfa can also be used. Treatment is aimed at HBeAg seroconversion, but most patients may need to continue antiviral therapy indefinitely.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6909",
      "difficulty": "easy"
    },
    {
      "text": "A 32-year-old man presented with complaints of fatigue for the past 1 month. His lab reports are given below. What is the most appropriate next step in the management of this patient?<div class='question-desc-html'><p>Total bilirubin - 1.2 mg/dL</p>\n<p>ALT - 30 IU/L</p>\n<p>HBsAg - positive</p>\n<p>HBeAg - negative</p>\n<p>HBV DNA - 1400 IU/mL</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir"
        },
        {
          "id": 2,
          "text": "Lamivudine and IFN"
        },
        {
          "id": 3,
          "text": "Entecavir"
        },
        {
          "id": 4,
          "text": "Serial monitoring"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>HBeAg negative and HBV DNA &lt;2000 IU/mL is suggestive of <strong>HBV carrier.</strong> Serial <strong>monitoring</strong> of both biochemical and virological parameters is done for such patients.</p>\n<p>Indications for starting antiviral therapy in chronic hepatitis B are:</p>\n<ul>\n<li aria-level=\"1\">Patients without cirrhosis</li>\n<ul>\n<li aria-level=\"2\"><strong>HBeAg +</strong> with <strong>HBV DNA &gt;20,000 IU/mL</strong> and ALT level &gt;2 times the upper limit of normal</li>\n<li aria-level=\"2\">HBeAg -ve with HBV DNA &gt;2000 IU/mL and ALT level &gt;2 times the upper limit of normal</li>\n</ul>\n<li aria-level=\"1\">Patients with compensated cirrhosis and an HBV DNA &gt;2000 IU/mL</li>\n<li aria-level=\"1\">Patients developing acute liver failure or decompensated cirrhosis</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6908",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is recommended as first-line therapy in a patient with chronic hepatitis B?",
      "choices": [
        {
          "id": 1,
          "text": "Pegylated interferon"
        },
        {
          "id": 2,
          "text": "Telbivudine"
        },
        {
          "id": 3,
          "text": "Lamivudine"
        },
        {
          "id": 4,
          "text": "Entecavir"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>First-line</strong> drugs used&nbsp;for the&nbsp;treatment of <strong>chronic hepatitis B&nbsp;</strong>include <strong>entecavir</strong> and tenofovir.</p>\n<p><strong>Second-line</strong> drugs for this condition include:</p>\n<ul>\n<li>Lamivudine</li>\n<li>Adefovir</li>\n<li>Telbivudine&nbsp;</li>\n</ul>\n<p>Pegylated interferon can also be used in its treatment.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6910",
      "difficulty": "medium"
    },
    {
      "text": "In which of the following populations should surveillance for hepatocellular carcinoma be done?<div class='question-desc-html'><ol>\n<li>HBV carriers with cirrhosis</li>\n<li>Asian male HBV carriers between ages of 30-40 years</li>\n<li>Asian female HBV carriers over age 50</li>\n<li>HBV carriers with a family history of HCC</li>\n<li>Patients with high serum levels of HBV DNA and ongoing liver injury</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "2, 3, 4"
        },
        {
          "id": 3,
          "text": "1, 2, 4, 5"
        },
        {
          "id": 4,
          "text": "1, 2, 3"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Surveillance</strong> for <strong>hepatocellular carcinoma</strong> is<strong> </strong>recommended for <strong>Asian male HBV</strong> <strong>carriers</strong> <strong>over </strong>the age of<strong> 40 years</strong>. </p>\n<p>The <strong>most common etiological</strong> factor for<strong> hepatocellular carcinoma</strong> in the world is the <strong>hepatitis B virus </strong>(HBV) <strong>infection</strong>. Surveillance programs have been implemented to screen for HCC in high-risk individuals because it is more cost-effective than the treatment of HCC.</p>\n<p>Surveillance for hepatocellular carcinoma (HCC) is recommended in:</p>\n<ul>\n<li>HBV carriers with cirrhosis</li>\n<li>Patients with high serum levels of HBV DNA and ongoing liver injury</li>\n<li>HBV carriers born in Africa and over the age of 20</li>\n<li>Asian male HBV carriers over age 40</li>\n<li>Asian female HBV carriers over age 50</li>\n<li>HBV carriers with a family history of HCC</li>\n</ul>\n<p>Note: <br />The CDC recently updated its guidelines for Hepatitis B screening. The report includes screening for all adults <span>&gt;</span>18 years old using the triple-panel test (HBsAg, Anti-HBs, total anti-HBc) and expanded risk-based testing in certain high-risk populations.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1001",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old male comes to the OPD with intermittent jaundice for the past 2 months. You suspect acute viral hepatitis. Which of the following will you not evaluate in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg"
        },
        {
          "id": 2,
          "text": "IgM anti HBc"
        },
        {
          "id": 3,
          "text": "Anti HCV"
        },
        {
          "id": 4,
          "text": "IgM anti HBe"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>IgM anti-HBe is not one of the markers that are evaluated in a suspected case of acute viral hepatitis.</p>\n<p><strong>Investigations</strong> done in suspected&nbsp;<strong>acute viral hepatitis</strong> are:</p>\n<ul>\n<li><strong>IgM anti-HAV </strong>-&nbsp;to detect acute hepatitis A infection which is the most common cause of acute hepatitis in children</li>\n<li><strong>HBsAg </strong>and<strong> IgM anti-HBc&nbsp;</strong>- to detect acute hepatitis B infection, where HbsAg is the first marker to rise and IgM anti-HBcAg is the most reliable marker of acute infection</li>\n<li><strong>Anti HCV&nbsp;</strong>- to evaluate for acute hepatitis C infection</li>\n<li><strong>IgM</strong> <strong>anti-HEV&nbsp;</strong>(rarely)-&nbsp;to detect acute hepatitis E infection which&nbsp;is one of the causes of acute viral hepatitis in adults.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0970",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old male chronic smoker presents to the AIIMS OPD with fever, fatigue, yellow-colored urine, and clay-colored stools. For the past few days, he has developed an aversion to cigarette smoking. On examination icterus was present. What investigations would you advise to rule out acute viral hepatitis? Liver function test results are given below:<div class='question-desc-html'><p>Total Bilirubin – 18.5 <br />Direct Bilirubin – 7.5 <br />SGOT – 723 <br />SGPT – 812</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg, IgM antiHBC, AntiHCV, AntiHEV"
        },
        {
          "id": 2,
          "text": "AntiHAV, HBsAg, IgM antiHBc, AntiHCV"
        },
        {
          "id": 3,
          "text": "HBsAg, IgM antiHBc, AntiHDV, AntiHCV, Anti HEV"
        },
        {
          "id": 4,
          "text": "AntiHAV, IgM antiHBc, AntiHCV, AntiHEV"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of <strong>jaundice</strong>. The<strong> tests</strong> that should be done in this patient to rule out <strong>acute viral hepatitis </strong>include:</p>\n<ul>\n<li>Anti-HAV</li>\n<li>HBsAg</li>\n<li>IgM anti-HBc</li>\n<li>Anti-HCV</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td><strong>Condition Suspected</strong></td>\n<td><strong>Targetted Test Performed</strong></td>\n</tr>\n<tr>\n<td>Acute Hepatitis A</td>\n<td>IgM Anti-HAV</td>\n</tr>\n<tr>\n<td>Acute Hepatitis B</td>\n<td>\n<p>HBsAg and</p>\n<p>IgM Anti-HBc</p>\n<p>*1 or both can be positive. A positive IgM AntiHBc with negative HBsAg is seen when HBsAg is below the detection threshold. </p>\n</td>\n</tr>\n<tr>\n<td>Acute Hepatitis C</td>\n<td>Anti HCV</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>We mainly test for hepatitis A, B, and C. Tests for hepatitis D and E are not used routinely.</p>\n<p><strong>Hepatitis D</strong> only occurs concurrently with Hepatitis B, either as a co-infection (when it is clinically indistinguishable from HBV infection) or superimposed on chronic HBV infection. In the latter scenario, it presents as a sudden worsening of the patient’s condition. IgM anti-HDV, IgG anti-HDV, and HDV RNA assays are useful for diagnosis when hepatitis D is suspected.</p>\n<p><strong>Hepatitis E</strong> is <strong>not tested</strong> as the majority of patients who acquire hepatitis E virus (HEV) infection spontaneously clear the virus. Acute hepatic failure is more likely in those who are pregnant and in those who are malnourished or have preexisting liver disease. Chronic HEV has been described almost exclusively in immunocompromised hosts (e.g., organ transplantation). The diagnosis of acute HEV is typically based upon the detection of IgM antibodies to HEV. <strong>B</strong><strong>oth false positives </strong>and <strong>negatives </strong>are<strong> common</strong> with available assays and are thus, not very reliable. Thus, additional serologic testing or HEV RNA testing should be performed to confirm the diagnosis and not be useful as a screening test. [Please note the difference between anti-HBe and anti-HEV]</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p> </p>\n<table>\n<tbody>\n<tr>\n<td> <strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5303",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following groups of individuals need not be screened for Hepatitis C infection?",
      "choices": [
        {
          "id": 1,
          "text": "Patients with HIV infection"
        },
        {
          "id": 2,
          "text": "Patients with unexplained elevation of aminotransferase levels"
        },
        {
          "id": 3,
          "text": "Patients who have undergone long-term haemodialysis"
        },
        {
          "id": 4,
          "text": "Household contacts of patients with hepatitis C"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>HCV screening is not indicated for household contacts of persons with hepatitis C.&nbsp;However, <strong>hepatitis B virus screening</strong> is recommended in <strong>household contacts </strong>of<strong> HBV-infected</strong> persons.</p>\n<p><strong>Indications</strong> <strong>of HCV infection</strong> <strong>screening</strong>:</p>\n<ul>\n<li>Persons with a history of using injection drugs</li>\n<li>Persons with<strong> HIV</strong> <strong>infection</strong></li>\n<li><strong>Long term hemodialysis</strong></li>\n<li>Persons with<strong>&nbsp;</strong>an <strong>unexplained elevation</strong> of <strong>aminotransferases</strong></li>\n<li>Recipient of blood or organs from a donor found to be positive for hepatitis C</li>\n<li>Children born to women with Hepatitis C</li>\n<li>Health care, public safety, and emergency medical personnel following needle injury or mucosal exposure to HCV contaminated blood</li>\n<li>Sexual partners of persons with Hepatitis C</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6899",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is unlikely to be seen as an extrahepatic manifestation in patients with hepatitis C infection?",
      "choices": [
        {
          "id": 1,
          "text": "Mixed cryoglobulinemia"
        },
        {
          "id": 2,
          "text": "Lichen planus"
        },
        {
          "id": 3,
          "text": "Porphyria cutanea tarda"
        },
        {
          "id": 4,
          "text": "Polyarteritis nodosa"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Polyarteritis nodosa</strong>&nbsp;is not characteristically associated with hepatitis C infection. However, it is a common extrahepatic manifestation of <strong>hepatitis B</strong> viral infection.</p><hr><h3>Related Pearl: Extrahepatic Manifestations of Hepatitis B and C</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Hepatitis B</strong></td>\n<td><strong>Hepatitis C</strong></td>\n</tr>\n<tr>\n<td>Hematological</td>\n<td>\n<p>Aplastic anemia</p>\n</td>\n<td>\n<p>Essential mixed cryoglobulinemia</p>\n</td>\n</tr>\n<tr>\n<td>Renal</td>\n<td>\n<p>Membranous glomerulonephritis (hepatitis B &gt; C)</p>\n<p>Membranoproliferative glomerulonephritis</p>\n</td>\n<td>\n<p>Membranoproliferative glomerulonephritis</p>\n<p>Membranous glomerulonephritis &nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>Vascular</td>\n<td>\n<p>Polyarteritis nodosa (hepatitis B&gt;C)</p>\n</td>\n<td>\n<p>Leukocytoclastic vasculitis</p>\n</td>\n</tr>\n<tr>\n<td>Dermatologic</td>\n<td>\n<p>Erythema multiforme (Hepatitis B&gt;C)</p>\n<p>Urticaria</p>\n<p>Serum sickness</p>\n<p>Infantile papular acrodermatitis (Gianotti&ndash;Crosti syndrome)</p>\n<p>Erythema nodosum</p>\n</td>\n<td>\n<p>Erythema multiforme</p>\n<p>Sporadic porphyria cutanea tarda</p>\n<p>Lichen planus</p>\n<p>Necrolytic acral erythema</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Hepatitis C also increases the risk of:</p>\n<ul>\n<li>Non-Hodgkin&rsquo;s lymphoma</li>\n<li>Idiopathic thrombocytopenic purpura</li>\n<li>Autoimmune hemolytic anemia</li>\n<li>Diabetes mellitus</li>\n<li>Autoimmune thyroiditis &nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6888",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old man who presented with weight loss and abdominal discomfort is diagnosed with chronic hepatitis C .  All the following factors can determine the progression of liver disease in this patient except:",
      "choices": [
        {
          "id": 1,
          "text": "Age"
        },
        {
          "id": 2,
          "text": "Duration of infection"
        },
        {
          "id": 3,
          "text": "HCV RNA level"
        },
        {
          "id": 4,
          "text": "Body mass index"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>While <strong>HCV RNA</strong> is considered the gold standard for establishing a <strong>diagnosis </strong>of<strong> hepatitis C</strong>, it has <strong>no role</strong> in determining the <strong>progression</strong> of liver disease in patients with chronic hepatitis C.</p>\n<p>The<strong> likelihood of&nbsp;progression</strong> of liver disease in patients with chronic hepatitis C is<strong>&nbsp;increased by:</strong></p>\n<ul>\n<li>Longer duration of infection - most important determinant</li>\n<li>Older age</li>\n<li>Obesity&nbsp;- patients with a high body mass index are at an increased risk of developing fibrosis</li>\n<li>Diabetes mellitus and insulin resistance</li>\n<li>Concomitant liver disorder (eg., alcoholic liver disease, chronic hepatitis B, hemochromatosis)</li>\n<li>Concomitant HIV infection.</li>\n</ul>\n<p>The <strong>best prognostic indicator</strong> in chronic hepatitis C is the <strong>rate of fibrosis</strong> and <strong>baseline inflammation</strong> seen in liver histology.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6900",
      "difficulty": "hard"
    },
    {
      "text": "A 47-year-old man presented with generalized weakness, fatigue, and fever. His lab investigations are given below. What is the preferred treatment regimen for this patient?<div class='question-desc-html'><p>ALT - 35 IU/L</p>\n<p>HCV - detectable</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Velpatasvir and sofosbuvir"
        },
        {
          "id": 2,
          "text": "Ribavirin and lamivudine"
        },
        {
          "id": 3,
          "text": "Telaprevir and simeprevir"
        },
        {
          "id": 4,
          "text": "α-interferon and dasabuvir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario is suggestive of hepatitis C for which the preferred treatment regimen is<strong> velpatasvir&nbsp;100 mg&nbsp;</strong>and<strong>&nbsp;sofosbuvir&nbsp;400 mg</strong>.&nbsp;</p>\n<p>The goal of treatment is a <strong>sustained virologic response</strong> (SVR), which is defined as the absence of a virus in the blood (undetectable HCV RNA), 12 weeks after completion of treatment. This can be achieved by the use of <strong>pan-genotypic</strong> <strong>directly acting</strong> antiviral drugs, irrespective of the disease stage.</p><hr><h3>Related Pearl: Direct acting antivirals (DAA) - Drugs against Hepatitis-C virus</h3><p>The directly acting antivirals used in the treatment of Hepatitis C infection include:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Mechanism of action&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Example</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5A inhibitors (asvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Velpatasvir</strong></li>\n<li>Daclatasvir</li>\n<li>Ledipasvir</li>\n<li>Ombitasvir</li>\n<li>Elbasvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Sofosbuvir</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B non nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li>Dasabuvir</li>\n<li>Beclabuvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS3/4A inhibitors (previr)</p>\n</td>\n<td>\n<ul>\n<li>Boceprevir</li>\n<li>Telaprevir</li>\n<li>Simeprevir</li>\n<li>Paritaprevir</li>\n<li>Asunaprevir</li>\n<li>Grazoprevir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;The following combinations of antiviral drugs can be used:</p>\n<ul>\n<li aria-level=\"1\">Acute, chronic hepatitis, or compensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) x 12 weeks.</li>\n</ul>\n</li>\n<li aria-level=\"1\">Decompensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) + Ribavirin (syntheticnucleotide analogue) x 12 weeks.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6895",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a non-structural protein 5A inhibitor used in the treatment of patients with hepatitis C infection?",
      "choices": [
        {
          "id": 1,
          "text": "Sofosbuvir"
        },
        {
          "id": 2,
          "text": "Daclatasvir"
        },
        {
          "id": 3,
          "text": "Ledipasvir"
        },
        {
          "id": 4,
          "text": "Velpatasvir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Sofosbuvir </strong>is not an NS5A inhibitor but is an&nbsp;<strong>NS5B </strong>nucleoside/nucleotide<strong> polymerase inhibitor</strong>.</p>\n<p>The directly acting antivirals used in the treatment of Hepatitis C infection include:</p><hr><h3>Related Pearl: Direct acting antivirals (DAA) - Drugs against Hepatitis-C virus</h3><p>The directly acting antivirals used in the treatment of Hepatitis C infection include:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Mechanism of action&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Example</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5A inhibitors (asvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Velpatasvir</strong></li>\n<li>Daclatasvir</li>\n<li>Ledipasvir</li>\n<li>Ombitasvir</li>\n<li>Elbasvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Sofosbuvir</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B non nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li>Dasabuvir</li>\n<li>Beclabuvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS3/4A inhibitors (previr)</p>\n</td>\n<td>\n<ul>\n<li>Boceprevir</li>\n<li>Telaprevir</li>\n<li>Simeprevir</li>\n<li>Paritaprevir</li>\n<li>Asunaprevir</li>\n<li>Grazoprevir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;The following combinations of antiviral drugs can be used:</p>\n<ul>\n<li aria-level=\"1\">Acute, chronic hepatitis, or compensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) x 12 weeks.</li>\n</ul>\n</li>\n<li aria-level=\"1\">Decompensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) + Ribavirin (syntheticnucleotide analogue) x 12 weeks.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6897",
      "difficulty": "medium"
    }
  ]
}